Drug development for neglected diseases: a deficient market and a public-health policy failure

Murray, 2001, 490

1996, Adhoc Committee (of the WHO) on health research relating to future intervention options

Janssens, 1992, 590

Pecoul, 1999, Access to essential drugs in poor countries: a lost battle?, JAMA, 281, 361, 10.1001/jama.281.4.361

Trouiller, 1999, Drug development output from 1975 to 1996: what proportion for tropical diseases?, Int J Infect Dis, 3, 61, 10.1016/S1201-9712(99)90010-3

Folkers, 2001, The AIDS research model: implications for other infectious diseases of global health importance, JAMA, 286, 458, 10.1001/jama.286.4.458

Health

2001

Anderson, 1996

DiMasi, 2001, New drug development in the United States from 1963 to 1999, Clin Pharm Ther, 69, 286, 10.1067/mcp.2001.115132

Stephenson, 2000, Drug treatment for tropical parasitic infections: recent achievements and developments, Drugs, 60, 985, 10.2165/00003495-200060050-00002

Vial, 1999, Renewed strategies for drug development against parasitic diseases, Parasitol Today, 10, 393, 10.1016/S0169-4758(99)01524-0

Wirth, 2001

1996

DiMasi, 1995, R&D costs innovative output, and firm size in the pharmaceutical industry, Int J Econ Bus, 2, 201, 10.1080/758519309

Kanavos, 1999

1997, 9

2000

Webber, 2001, Perspectives on stimulating industrial research and development for neglected infectious diseases, Bull World Health Organ, 79, 735

Haffner, 1998, Orphan drug development: international program and study design issues, Drug Inf J, 32, 93, 10.1177/009286159803200113

Trouiller, 1999, Is orphan drug status beneficial to tropical diseases control? Comparison of the American and future European orphan drug acts, Trop Med Int Health, 4, 412, 10.1046/j.1365-3156.1999.00420.x

Goldman, 1992, Creating the costliest orphan: the Orphan Drug Act in the development of Ceredase, Int J Tech Assess Health Care, 8, 583, 10.1017/S0266462300002294

Makinen, 2000, Inequalities in healthcare use and expenditures: empirical data from eight developing countries and countries in transition, Bull World Health Organ, 78, 55

DiMasi, 2001, Risks in new drug development: approval successes rates for investigational drugs, Clin Pharm Ther, 69, 297, 10.1067/mcp.2001.115446

Young, 2001

Drews, 1998, Innovation deficit revisited: reflection on the productivity of pharmaceutical R&D, Drug Discov Today, 3, 491, 10.1016/S1359-6446(98)01252-5

Kadar, 1995, La Mutation du Marchè Mondial des Vaccins, Rev Prèscrire, 15, 844

2000

2001

Correa, 2000, The case of pharmaceuticals, 42

Kaitin, 2000, The new drug approvals of 1996, 1997, and 1998: drug development trends in the user fee era, Drug Inf J, 34, 1, 10.1177/009286150003400101

Buse, 2000, Global public-private partnerships, part II: what are the health issues for global governance?, Bull World Health Organ, 78, 699

Buse, 2000, Global public-private partnerships, part I: a new development in health?, Bull World Health Organ, 78, 549

Wheeler, 2001, Initial lessons from public-private partnerships in drug and vaccine development, Bull World Health Organ, 79, 728